PAVmed Inc. Stock price

Equities

PAVM

US70387R4039

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 10:43:05 2024-03-28 am EDT 5-day change 1st Jan Change
2.465 USD -9.71% Intraday chart for PAVmed Inc. +15.57% -40.53%
Sales 2024 * 6.81M Sales 2025 * 22.67M Capitalization 25.04M
Net income 2024 * -67M Net income 2025 * -55M EV / Sales 2024 * 3.68 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.1 x
P/E ratio 2024 *
-0.48 x
P/E ratio 2025 *
-0.79 x
Employees 124
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.54%
More Fundamentals * Assessed data
Dynamic Chart
1 day-9.71%
1 week+15.57%
Current month-7.55%
1 month-17.79%
3 months-40.10%
6 months-47.31%
Current year-40.53%
More quotes
1 week
2.00
Extreme 2.0001
2.84
1 month
1.85
Extreme 1.8537
3.50
Current year
1.60
Extreme 1.6
4.29
1 year
1.60
Extreme 1.6
9.36
3 years
1.60
Extreme 1.6
145.50
5 years
1.60
Extreme 1.6
145.50
10 years
1.60
Extreme 1.6
228.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 14-06-25
Director of Finance/CFO 67 17-03-20
Chief Tech/Sci/R&D Officer - 21-10-20
Members of the board TitleAgeSince
Director/Board Member 81 14-12-31
Director/Board Member 69 14-12-31
Director/Board Member 62 21-04-21
More insiders
Date Price Change Volume
24-03-28 2.45 -10.26% 47 160
24-03-27 2.73 +32.52% 438,513
24-03-26 2.06 -6.79% 33,843
24-03-25 2.21 +1.84% 46,041
24-03-22 2.17 +2.36% 20,449

Delayed Quote Nasdaq, March 28, 2024 at 10:25 am EDT

More quotes
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.73 USD
Average target price
22.5 USD
Spread / Average Target
+724.18%
Consensus
  1. Stock
  2. Equities
  3. Stock PAVmed Inc. - Nasdaq